Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

Pharmacogenomics: The End of Trial-and-Error Medicine?

Author(s):  Vail Jane

Issue:  Jan/Feb 2007 - Pediatric Patients
View All Articles in Issue

Page(s):  59-65

Download in electronic PDF format for $65

Abstract:  “The right dose of the right drug for the right indication for the right patient at the right time.” In those words, Dr. Felix Frueh captured the essence of pharmacogenomics and the goal of all compounding pharmacists. Pharmacogenomics provides the tools for prescribing personalized drug therapy that will improve treatment outcomes, decrease the incidence of drug-related adverse effects, and ultimately reduce the cost of medical care. The use of pharmacogenomics in clinical practice is changing as new discoveries make it possible and cost-effective to identify a patient’s unique genetic makeup and apply this information to treating medical ailments. With a prescription and the patient’s pharmacogenomic profile in mind, a compounding pharmacist can prepare a customized medication that delivers that patient’s unique best dosage in the optimal dosage form.

Related Keywords: PERSONALIZED MEDICINE, INDIVIDUALIZED MEDICINE, PHARMACOGENOMICS, GENOMICS, GENOME, GENETIC TESTING, RESEARCH, FDA, US FOOD AND DRUG ADMINISTRATION, TRIAL, CUSTOMIZED, JANET WOODCOCK

Related Categories: LEGAL, TECHNOLOGY, PROFESSIONAL ISSUES, PREVENTIVE MEDICINE/WELLNESS

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Personalized Medicine and Customized Drug Delivery Systems: The New Trend of Drug Delivery and Disease Management
Soni Abhishek
, Gowthamarajan Kuppusamy, Radhakrishnan Arun
Mar/Apr 2018
Pg. 108-121

Pharmacogenomics: The End of Trial-and-Error Medicine?
Vail Jane
Jan/Feb 2007
Pg. 59-65

Pharmacogenomics as a Competitive Strategy for Compounding Pharmacies
Maham Nicole Y
Nov/Dec 2022
Pg. 474-479

PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs
Allen Loyd V Jr
Sep/Oct 2017
Pg. 356

Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines
Allen Loyd V Jr
Jul/Aug 2016
Pg. 351

View Sample
Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed
Brunner Scott
Jul/Aug 2020
Pg. 296-297

Biotechnology, Nanotechnology, and Pharmacogenomics and Pharmaceutical Compounding, Part 2
Allen Loyd V
Jul/Aug 2015
Pg. 280-287

U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances
Miller David G
Jul/Aug 2015
Pg. 303-305

Pharmacogenomics: Precision Pharmacy in 503A Compounding
Drummond Joseph
, Bennet Daron, Allen Loyd V Jr
Mar/Apr 2018
Pg. 95-107

U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs
Allen Loyd V Jr
Nov/Dec 2015
Pg. 487-488

Particle Measuring Systems - USP <797> Environmental Monitoring Solutions